PRODUCT INFORMATION



WHI-P97

Item No. 36385

CAS Registry No.: 211555-05-4

2,6-dibromo-4-[(6,7-dimethoxy-4-Formal Name:

quinazolinyl)amino]-phenol

Synonym: HY-11067

MF: $C_{16}H_{13}Br_2N_3O_3$

FW: 455.1 **Purity:** ≥98% Supplied as: A solid Storage: -20°C Stability: ≥4 vears OH

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

WHI-P97 is supplied as a solid. A stock solution may be made by dissolving the WHI-P97 in the solvent of choice, which should be purged with an inert gas. WHI-P97 is soluble in the organic solvent DMSO at a concentration of approximately 3.33 mg/ml.

Description

WHI-P97 is an inhibitor of JAK3 (IC $_{50}$ = 11 μ M).¹ It inhibits leukotriene C $_4$ (LTC $_4$) and LTB $_4$ release, mediated by the high-affinity IgE receptor Fc ε receptor I (FcεRI), from RBL-2H3 mast cells when used at a concentration of 10 μM.2 It also inhibits FcεRI-mediated 5-lipoxygease (5-LO) translocation to the membrane in RBL-2H3 mast cells. In vivo, WHI-P97 (40 mg/kg) reduces antigen-induced LTC₄ production in IgE-sensitized mice. It also reduces airway hyperresponsiveness and bronchoalveolar lavage fluid (BALF) eosinophil infiltration in a mouse model of ovalbumin-induced allergic asthma when administered at doses of 12 and 40 mg/kg.

References

- 1. Sudbeck, E.A., Liu, X.P., Narla, R.K., et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin. Cancer Res. 5(6), 1569-1582 (1999).
- 2. Malaviya, R., Chen, C.-L., Navara, C., et al. Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7dimethoxyquinazoline (WHI-P97). J. Pharmacol. Exp. Ther. 295(3), 912-926 (2000).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 02/10/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM